Compass Therapeutics, Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for CMPX, updated each market day.
CMPX AI Sentiment
AI sees no strong directional signal for Compass Therapeutics, Inc. Common Stock stock over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Compass Therapeutics, Inc. Common Stock
Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.
Sector
Exchange
Market Cap
$981,479,136
Cap Tier
Employees
39
Headquarters
BOSTON, MA
Listed Since
Nov. 13, 2020
CMPX Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
CMPX Volatility
Compass Therapeutics, Inc. Common Stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
